Characteristics | Prone volumetric modulated arc therapy group (n = 12) | Supine box group (n = 6) |
---|---|---|
Age (years) | ||
Median | 52.5 | 57.5 |
Range | 38 to 72 | 53 to 71 |
Sex | ||
Male | 7 | 5 |
Female | 5 | 1 |
Clinical tumor stage | ||
T2 | 1 | 0 |
T3 | 8 | 5 |
T4 | 3 | 1 |
Clinical node stage | ||
N0 | 2 | 2 |
N1 | 2 | 4 |
N2 | 8 | 0 |
Clinical stage | ||
IIA | 2 | 2 |
IIIB | 6 | 2 |
IIIC | 4 | 0 |
IVA | 0 | 2 |
Distance from the anal verge | ||
< 5 cm | 5 | 1 |
5 to 10 cm | 7 | 4 |
≥ 10 cm | 0 | 1 |
Chemotherapy | ||
Bevacizumab + FOLFOX (leucovorin, fluorouracil, and oxaliplatin) | 11 | 6 |
Bevacizumab +5-fluorouracil | 1 | 0 |
Surgical type | ||
Lower anterior resection | 9 | 3 |
Abdominoperineal resection | 3 | 1 |